Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Max Healthcare and ImmunoACT Team Up to Roll Out CAR-T Cell Therapy

NextEdge Admin

09 Nov 2023

1 min 55 sec

Max Healthcare has launched the cutting-edge Chimeric Antigen Receptor (CAR)-T Cell Therapy, a revolutionary treatment for specific cancers, now available at all its hospitals in Delhi-NCR. This innovative therapy involves genetically engineering patients’ immune cells, particularly T cells, in the laboratory to empower them in fighting cancer. The sourcing of CAR T cells for this therapy is in collaboration with ImmunoACT, an IIT Bombay-incubated company, which recently received marketing authorization for its CAR-T cell therapy product targeting relapsed/refractory B-cell lymphomas and leukemia in India.

Often referred to as a “living drug,” CAR-T therapy provides enduring benefits and is recommended for individuals who cannot undergo a stem cell transplant or experience post-transplant relapse. Compared to conventional therapies, CAR-T treatment requires a brief, single-infusion approach, significantly reducing the in-patient care duration. This groundbreaking approach aligns with Max Healthcare’s commitment to pushing the boundaries of cancer treatment and offering patients the most advanced therapeutic options available. Dr. Harit K Chaturvedi, Chairman of Max Institute of Cancer Care, highlights the introduction of CAR T-cell therapy as a significant leap, reflecting the continuous endeavor to provide cutting-edge care for cancer patients and improve their quality of life.